Feds approve waiver for Alabama rail project amid automation concerns
The Alabama State Port Authority (ASPA), which will oversee the ICTF, told the Federal Railroad Administration that the waiver is necessary in order to purchase two rubber-tired gantry cranes it wants to install at the facility, located next to the main CSX rail line between Montgomery and Mobile, Alabama.
Projects receiving funding under FRA's Consolidated Rail Infrastructure and Safety Improvements (CRISI) program – ASPA received a $67.3 million CRISI grant for the project in 2022 – must adhere to the agency's Buy America requirements.
But FRA may waive those requirements if it determines that:Applying the Buy America requirements would be inconsistent with the public interest;
Steel, iron, and goods produced in the U.S. are not produced in a sufficient and reasonably available amount or are not of a satisfactory quality;
Rolling stock or power train equipment cannot be bought and delivered in the United States within a reasonable time; or
Including domestic material will increase the cost of the overall project by more than 25%.
'FRA has determined that the two rubber-tired gantry cranes, including spreaders, that meet ASPA's technical specifications are not produced in the United States in a sufficient and reasonably available amount or satisfactory quality' consistent with the regulation, FRA stated in a notice published on Wednesday.
'FRA finds ASPA has conducted appropriate due diligence through market research and an open procurement process to identify potential domestic suppliers for the products. ASPA's efforts included a market research study that identified one potential supplier; however, ASPA did not receive any responses to its RFP from domestic suppliers.'
The Transportation Trades Department (TTD), part of the AFL-CIO, which represents railroad employees, had protested the waiver last year, arguing that because ASPA's bid request stipulates that the cranes allow for future conversion to remote operations, a waiver 'may serve as a back door to securing federal funding for a huge share of the cost of equipment that will eventually be converted to semi-automated or automated functions.'
'Put simply, this strategy, if successful, would incentivize procurements that operators would not have made without the government's intervention,' asserted TTD President Greg Regan in comments filed with the FRA.'In other words, the federal government would be subsidizing the near-future elimination of jobs.'
Responding to TTD's concerns, FRA pointed out that the waiver does not set precedents and will expire upon the closeout of the grant award, estimated to be April 2028.
In addition, because the ICTF will serve international container traffic that passes through the Port of Mobile, Alabama, the waiver will help ASPA 'promote American jobs by supporting the transportation needs of Central Alabama's growing manufacturing, agricultural, and retail industries,' the agency stated.
Port of Mobile enters fourth phase of $104M container terminal expansion
$231M rail project to connect Port of Mobile to central Alabama
Port of Mobile awarded $300M for infrastructure, intermodal improvements
Click for more FreightWaves articles by John Gallagher.
The post Feds approve waiver for Alabama rail project amid automation concerns appeared first on FreightWaves.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a few seconds ago
- Yahoo
Hudbay Minerals (HBM) Climbs 15% on Stellar Earnings, $600-Million Investment From Mitsubishi
We recently published . Hudbay Minerals Inc. (NYSE:HBM) is one of the best-performing stocks on Wednesday. Hudbay Minerals grew its share prices for a second day on Wednesday, up 15.03 percent to close at $11.33 apiece, following an impressive earnings performance and a $600-million investment from Mitsubishi Corp. In its updated report, Hudbay Minerals Inc. (NYSE:HBM) said it swung to a net income attributable to shareholders of $117.7 million from an attributable net loss of $16.5 million in the same period last year, driven by higher gross margins and strong cost control. Revenues increased by 26 percent to $536.4 million from $425.5 million year-on-year. 'With the strong performance in the first half of the year, we are reaffirming our full year consolidated production guidance and are favourably tracking well below our full year consolidated cost guidance for 2025,' said Hudbay Minerals Inc. (NYSE:HBM) President and CEO Peter Kukielski. For the full-year period, the company is targeting to produce between 117,000 and 149,000 tons of copper, as well as 247,500 to 308,000 ounces of gold. In other news, Hudbay Minerals Inc. (NYSE:HBM) was able to raise $600 million in fresh funds from Mitsubishi Corp. after the latter acquired a 30-percent stake in Copper World LLC. Under the agreement, Mitsubishi will pay an upfront cash of $420 million, with the balance to serve as a matching contribution within an 18-month period. While we acknowledge the potential of HBM as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a few seconds ago
- Yahoo
Paramount Skydance (PSKY) Soars 60% to New High. Time to Book Gains?
We recently published . Paramount Skydance Corp. (NASDAQ:PSKY) is one of the best-performing stocks on Wednesday. Paramount Skydance extended its rally to touch a new high on Wednesday, finishing up by 36.74 percent at $15 apiece, with a former hedge fund manager calling it a 'meme' stock. In a social media post, Mad Money host and former hedge fund manager Jim Cramer said Paramount Skydance Corp. (NASDAQ:PSKY) is a 'meme stock' given the company's small public float and unjustifiable rally amid the lack of fresh developments. Paramount Skydance Corp. (NASDAQ:PSKY) climbed by as high as 60 percent at intra-day trading to hit $17.53 before paring gains to finish slightly lower during the session. In recent news, the company bagged a new $7.7-billion deal to exclusively air the Ultimate Fighting Championship (UFC) on Paramount+ for seven years beginning in 2026. The deal would include UFC's full slate of 13 marquee numbered events and 30 Fight Nights through its direct-to-consumer streaming platform, Paramount+, with select numbered events to be simulcast on CBS. cellanr, CC BY-SA 2.0 , via Wikimedia Commons As part of the agreement, Paramount Skydance Corp. (NASDAQ:PSKY) will move UFC away from the existing Pay-Per-View model and make the latter available at no additional cost to Paramount+ subscribers in the US. It also intends to explore UFC rights outside the US in the future. While we acknowledge the potential of PSKY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a few seconds ago
- Yahoo
ImmunityBio (IBRX) Jumps 14% as on Promising Therapy Candidate Results
We recently published . ImmunityBio, Inc. (NASDAQ:IBRX) is one of the best-performing stocks on Wednesday. ImmunityBio soared by 14.17 percent on Wednesday to close at $2.82 apiece as investors cheered promising early findings from its ongoing trial (QUILT-106) to treat a rare blood cancer type with its therapy candidate. In a statement, ImmunityBio, Inc. (NASDAQ:IBRX) said the first phase of QUILT-106 showed highly promising results in the first two patients with Waldenstrom macroglobulinemia (WM)—a type of non-Hodgkins lymphoma (NHL)—using its CD19 CAR-NK (CD19 t-haNK) natural killer cell therapy. The trial aims to evaluate the safety and efficacy of the cell therapy alone, as well as when it is combined with an existing drug called rituximab. According to ImmunityBio, Inc. (NASDAQ:IBRX), both patients tolerated the therapy candidate without any significant side effects. Notably, all infusions were administered in an outpatient setting. Copyright: katrintimoff / 123RF Stock Photo 'One patient achieved a complete response (CR) with CD19 CAR NK monotherapy, while the second patient achieved CR with CD19 CAR-NK in combination with rituximab. Remission was maintained and is ongoing for six months to date,' ImmunityBio, Inc. (NASDAQ:IBRX) said. While we acknowledge the potential of IBRX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data